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threats	 to	 human	 health.1	 According	 to	 a	 2017	 report	 from	 the	
Center	 for	 Disease	 Control	 and	 prevention	 (CDC)	 more	 than	 2	
million	 Americans	 acquire	 antibiotic-resistant	 infections	 each	 year	
leading	 to	 at	 least	 23,000	 deaths	 in	 the	 US	 alone.2	 Since	 the	 so-
called	 “golden	 age”	 of	 antibiotic	 discovery	 spanning	 the	 1940s-
1960s,	 very	 few	 new	 antibiotics	 operating	 with	 novel	 modes	 of	
action	have	been	introduced.3	Notable	in	this	regard	is	daptomycin,	
the	 preeminent	 calcium-dependent	 antibiotic	 (CDA)	 and	 the	most	
recent	 first-in-class	 antibiotic	 to	 have	 entered	 the	 clinic.4,5	
Daptomycin’s	 precise	 mechanism	 of	 action	 is	 a	 topic	 of	 some	
debate.6,7	 By	 comparison,	 the	 mode	 of	 action	 of	 the	 structurally	
similar	 CDA	 laspartomycin	 C	 (Fig	 1.)	 is	more	 clearly	 understood.8,9	
Unlike	daptomycin,	laspartomycin	C	specifically	targets	the	essential	
bacterial	 phospholipid	 undecaprenyl	 phosphate	 (C55-P).	 C55-P	
represents	 a	 novel	 target	 and	 to	 date	 there	 are	 no	 clinically	
approved	 antibiotics	 that	 operate	 by	 binding	 C55-P.	 Our	 group	
recently	 reported	 the	 first	 total	 synthesis	 of	 laspartomycin	 C10	 as	




with	 varying	 mechanisms	 of	 action,	 they	 share	 a	 number	 of	 key	
structural	similarities.	These	include	the	positioning	of	key	achiral	or	
D-amino	acids	as	well	as	the	highly	conserved	Asp-X-Asp-Gly	motif.12	
This	 Asp-X-Asp-Gly	 sequence	 is	 essential	 for	 the	 calcium	 binding	
that	 all	 CDAs	 utilize	 in	 achieving	 their	 full	 antibacterial	 activity.	 In	
the	 absence	 of	 calcium,	 the	 activity	 of	 the	 CDAs	 is	 significantly	
reduced	 or	 completely	 lost.13	 Figure	 1	 presents	 the	 structure	 of	
laspartomycin	 C	 and	 highlights	 the	 structural	 features	 common	 to	
many	CDAs.		
At	 present	 there	 are	more	 than	 40	 unique	 CDAs	 known	 and	 their	
structural	 diversity	 continues	 to	 provide	 great	 opportunity	 for	
discovery.14	 All	 CDAs,	 except	 for	 the	 newly	 reported	 malacidins,	
contain	10	amino	acids	in	their	macrocycle.	Using	the	macrocycle	of	
laspartomycin	 C	 as	 a	 reference	 point	 it	 can	 be	 noted	 that:	 1)	 The	
majority	 of	 CDAs	 bear	 an	 L-amino	 acid	 at	 position	 4	 (usually	 an	
ornithine,	alanine,	aspartic	acid,	or	β-methyl-aspartic	acid)	with	the	
exception	 being	 the	 laspartomycins	 which	 include	 a	 glycine	 at	
position	4;	2)	position	6	is	nearly	always	a	D-amino	acid,	again	with	





























































































































































































	 0	 2.5	 5.0	 10	
1	(LaspC)		 ≥128	 4	 4	 2	
2	 ≥128	 16	 16	 16	
3	 ≥128	 64	 32	 32	
4	 ≥128	 ≥128	 ≥128	 ≥128	
5	 64	 64	 64	 64	
6	 ≥128	 ≥128	 ≥128	 ≥128	
7	 ≥128	 ≥128	 ≥128	 ≥128	





us	 to	 investigate	 the	 contribution	 that	 the	 absence	 of	 chirality	 at	
these	 positions	 has	 on	 antibacterial	 activity.	 To	 this	 end	 we	
investigated	 the	 introduction	of	 the	achiral	 2-aminoisobutyric	 acid	
(Aib)	at	these	positions	as	well	as	the	introduction	of	either	L-	or	D-
alanine	residues.	We	here	describe	the	preparation	and	evaluation	
of	 a	 series	 of	 novel	 laspartomycin	 analogues	 that	 provide	 new	
stereochemical	structure-activity	insights	at	positions	4,	6,	and	8.		
Results	and	discussion	
To	 evaluate	 the	 role	 of	 the	 three	 achiral	 centers	 in	 the	
laspartomycin	 C	macrocycle	we	 began	 by	 preparing	 a	 series	 of	
analogues	 containing	 the	 achiral	 amino	 acid	 2-aminoisobutyric	
acid	(Aib)	at	each	position.	These	laspartomycin	C	variants	were	
prepared	 using	 a	 robust	 combined	 solid-	 and	 solution-phase	
approach	 that	 our	 group	 as	 well	 as	 Payne	 and	 coworkers	
previously	 described	 (Scheme	 1).15,16	 The	 linear	 lipopeptide	
precursors	were	first	assembled	on	solid	support	using	the	acid	
sensitive	2-chlorotrityl	resin.	Starting	from	C-terminal	Pro11	each	
peptide	 was	 assembled	 using	 standard	 Fmoc-SPPS	 strategies	
with	the	notable	introduction	of	an	Alloc	side	chain	protected	L-
diaminopropioinc	 acid	 (L-Dap)	 residue	 at	 position	 2.	 Also,	 for	
analogues	containing	Gly	at	positions	6	and/or	8	(compounds	1-
6)	 DMB-Gly	 was	 employed	 to	 avoid	 aspartamide	 formation.	
Following	 N-terminal	 lipidation,	 the	 Alloc	 side	 chain	 protecting	
of	 L-Dap2	 was	 removed	 and	 the	 partially	 protected	 peptide	
released	 from	 the	 resin	 using	 mildly	 acidic	 conditions.	 The	
partially	protected	peptide	was	then	cyclized	at	high	dilution	by	
treatment	 with	 BOP/DIPEA	 resulting	 in	 the	 clean	 formation	 of	
the	 macrocyclic	 product.	 Global	 deprotection	 followed	 by	 RP-
HPLC	purification	provided	the	various	laspartomycin	analogues	
in	yields	ranging	from	5-13%.	
To	 assess	 the	 contribution	 of	 the	 achiral	 positions	 4,	 6,	 and	 8,	
analogues	2-8	were	prepared	wherein	 one	or	more	of	 the	 glycine	
residues	 was	 replaced	 by	 the	 achiral	 Aib.	 The	 rationale	 for	 this	
replacement	 related	 to	 the	 previously	 reported	 ability	 of	 the	 Aib	
residue	 to	 predispose	 peptides	 towards	 their	 active	
conformation(s).17	 The	 antimicrobial	 activity	 of	 analogues	2-8	 was	
compared	with	that	of	authentic	 laspartomycin	C	 (Table	1)	using	a	
serial	 dilution	 assay	 employing	 a	 clinically	 relevant	 strain	 of	
Methicillin-resistant	 Staphylococcus	 aureus	 (MRSA).	 Analogues	 2	
and	 3	 were	 found	 to	 exhibit	 calcium-dependent	 activity,	 albeit	
significantly	 less	 than	 laspartomycin	 C,	 while	 analogues	 4-8,	 were	
essentially	 devoid	 of	 activity.	 Interesting,	 analogues	2	 and	3,	 both	
containing	 a	 single	 Aib	 at	 position	 4	 and	 6	 respectively,	 maintain	
some	activity.	Conversely,	Aib	substitution	at	position	8	as	in	analog	
4	 led	 to	 complete	 loss	 of	 activity.	 Notably,	 analogue	 8	 containing	
Aib	at	all	three	positions,	exhibits	modest	activity	while	showing	no	
Ca2+	 dependency.	 These	 results	 indicate	 that	 modification	 at	
positions	 4	 and	 6	 can	 compensate	 for	 an	 otherwise	 detrimental	
modification	at	position	8.		
All	known	CDAs	contain	a	glycine	at	position	8	which	is	part	of	the	
Asp-X6-Asp-Gly8	 calcium	 binding	 region.	 It	 therefore	 stands	 to	
reason	 that	 changes	 at	 position	 8	 significantly	 impact	 in	 the	
peptide’s	ability	to	chelate	calcium	and	bind	to	 its	bacterial	target.	
In	 this	 regard	 it	 is	 notable	 that	 position	 6,	 also	 part	 of	 the	 CDA	
calcium	binding	 region,	 is	more	amenable	 to	variation.	 In	 the	case	
of	 the	 laspatomycins,	 friulimicins,	 and	 amphomycins	 the	 inclusion	
of	Gly	at	position	6	sets	them	apart	from	the	majority	of	other	CDAs	
which	 generally	 contain	 a	 D-amino	 acid	 at	 this	 site.	 In	 the	 case	 of	
daptomycin	 D-alanine	 is	 found	 at	 position	 6	 while	 in	 the	 A54145	
class	 it	 is	D-lysine	and	in	the	confusingly	named	“CDA-class”	 it	 is	D-
phenylglycine.18	 With	 this	 in	 mind	 we	 prepared	 four	 additional	


















































































ii) iii) iv) v)
1: A,B,C = Gly (Laspartomycin C)
2: A = Aib, B,C = Gly
3: A,C = Gly, B = Aib
4: A,B = Gly, C = Aib
5: A,B = Aib, C = Gly
6: A,C = Aib, B = Gly
7: A = Gly, B,C = Aib










































































































































	 0	 2.5	 5.0	 10	
1	(LaspC)		 ≥128	 8	 4	 2	
9	 ≥128	 16	 8	 4	
10	 ≥128	 16	 8	 2	
11	 ≥128	 64	 32	 16	
12	 64	 16	 8	 1	
a	Minimum	inhibitory	concentrations	reported	in	μg/mL	against	MRSA	
USA300	at	calcium	concentration	indicated.	
The	 antimicrobial	 activity	 of	 analogues	 9-12	 was	 compared	 with	
that	of	authentic	laspartomycin	C	(Table	2).	Using	the	same	activity	




alanine	 at	 position	 4	 yields	 compounds	 of	 similar	 activity	while	 at	
position	 6	 the	 D-Ala	 variant	 was	 16-fold	 more	 active	 than	 the	 L-





and	 8	 positions	 on	 antibacterial	 activity.	 Using	 a	 combined	 solid-	
and	 solution-phase	 approach,	 analogues	 were	 first	 prepared	
wherein	positions	4,	6	and	8	were	modified	 to	 contain	 the	achiral	
amino	acid	Aib.	These	analogues	showed	a	significant	 reduction	 in	
activity	compared	to	the	parent	compound.	Incorporation	of	Aib	at	
position	 8	 led	 to	 complete	 loss	 of	 activity	 while	 the	 same	
modification	at	positions	4	or	6	led	to	analogues	that	retained	some	
activity.	 A	 second	 series	 of	 analogues	 incorporating	 either	 D	 or	 L-
alanine	at	positions	4	and	6	were	also	prepared.	The	introduction	of	
both	 D-	 and	 L-Ala	 at	 position	 4	 led	 to	 compounds	 that	 showed	
activity	similar	to	laspatpomcyin	C.	However,	at	position	6	the	D-Ala	
variant	 is	 16-times	 more	 active	 than	 the	 L-Ala	 and	 even	 showed	
slightly	better	activity	than	laspartomycin	C.		
While	 the	 various	 members	 of	 the	 CDA	 family	 contain	 diverse	
amino	acids	at	position	4	they	are	always	either	glycine	or	a	L-amino	
acid.	 Our	 findings	 indicate	 that	 the	 incorporation	 of	 D-Ala	 at	
position	4	does	not	negatively	affect	activity.	Position	6	plays	a	key	
role	 in	 the	 calcium-binding	 motif	 (Asp-X6-Asp-Gly)	 and	 is	 always	
either	 a	 glycine	 of	 a	 D-amino	 acid.	 Our	 findings	 demonstrate	 that	
positions	4	and	6	of	Laspartomycin	C	are	amenable	to	substitution	
provided	 the	 correct	 stereochemical	 constraints	 are	 respected.	 To	
this	end	ongoing	studies	in	our	laboratory	are	aimed	at	establishing	




Chlorotrityl	 resin	 (5.0	 g,	 1.60	mmol/g)	was	 loaded	with	 Fmoc-Pro-
OH.	Resin	loading	was	determined	to	be	0.41-0.62	mmol.g-1.	Linear	
peptide	 encompasing	 Pro11	 to	Asp1	were	 assembled	manualy	 via	
standard	 Fmoc	 solid-phase	 peptide	 synthesis	 (SPPS)	 (resin	 bound	
AA:Fmoc-AA:BOP:DiPEA,	 1:4:4:8	 molar	 eq.)	 on	 a	 0.1	 mmol	 scale.	
DMF	was	used	as	solvent	and	Fmoc	deprotections	were	carried	out	
with	 piperidine:DMF	 (1:4	 v:v).	 Amino	 acid	 side	 chains	 were	
protected	as	follows:	 tBu	for	Asp,	Alloc	for	DAP,	and	DMB	for	Gly6	
and	Gly8.	D-allo-Thr	was	introduced	without	side	chain	protection.	
Following	 coupling	 and	 Fmoc	 deprotection	 of	 Asp1,	 N-terminal	
acylation	 was	 achieved	 by	 coupling	 (E)-13-methyltetradec-2-enoic	





of	diethyldithiocarbamic	acid	 trihydrate	 sodium	salt	 (5	mg	mL-1	 in	
DMF,	 5x10	 mL),	 and	 DMF	 (5x10	 mL).	 The	 resin	 was	 treated	 with		
(CF₃)₂CHOH:CH2Cl2	 (1:4,	 10	 mL)	 for	 1	 hour	 and	 rinsed	 with	
additional	 (CF₃)₂CHOH:CH2Cl2	 and	 CH2Cl2.	 The	 combined	 washings	
were	 then	 evaporated	 to	 yield	 the	 linear	 protected	 peptide	 with	
free	C-	and	N-termini.	The	residue	was	dissolved	in	CH2Cl2	(150	mL)	
and	 treated	with	BOP	 (0.22	 g,	 0.5	mmol)	 and	DiPEA	 (0.17	mL,	 1.0	
mmol)	 and	 the	 solution	 was	 stirred	 overnight	 after	 which	 TLC	
indicated	 complete	 cyclization.	 The	 reaction	 mixture	 was	
concentrated	and	directly	 treated	with	TFA:TIS:H2O	 (95:2.5:2.5,	10	
mL)	 for	 90	 minutes.	 The	 reaction	 mixture	 was	 added	 to	
MTBE:hexanes	 (1:1)	 and	 the	 resulting	 precipitate	 washed	 once	
more	 with	 MTBE:hexanes	 (1:1).	 The	 crude	 cyclic	 peptide	 was	
lyophilized	 from	 tBuOH:H2O	 (1:1)	 and	 purified	 with	 reverse	 phase	
HPLC.	 Pure	 fractions	 were	 pooled	 and	 lyophilized	 to	 yield	 the	




Minimum	 inhibitory	 concentrations	 (MICs)	 were	 determined	 by	
broth	microdilution	according	to	CLSI	guidelines.17	Blood	agar	plates	








































9: A = L-Ala, B = Gly
10: A = D-Ala, B = Gly
11: A = Gly, B = L-Ala
12: A = Gly, B = D-Ala




































































































































16	 hours	 at	 37°C	 and	 30°C	 respectively.	 Cation	 adjusted	Mueller-
Hinton	broth	(MHB)	containing	10	mg.L-1	Mg2+	was	inoculated	with	
individual	 colonies	 of	 S.	 aureus	 and	Methicillin-resistant	 S.	 aureus	
(MRSA	 USA300),	 and	 incubated	 for	 16	 hours	 at	 220	 RPM.	 The	
peptides	 were	 dissolved	 in	 MHB	 (10	 mg.L-1	 Mg2+)	 and	 serially	
diluted	on	polypropylene	microtiter	plates	with	a	volume	of	50	μL	
per	 well.	 Inoculated	 MHB	 (2x105	 CFU.mL-1)	 containing	 10	 mg.L-1	
Mg2+	 and	 varying	 concentrations	 of	 Ca2+	 (0-10	mM)	was	 added	 to	
reach	a	total	volume	of	100	μL	per	well.	The	microtiter	plates	were	
sealed	 with	 an	 adhesive	 membrane	 and	 after	 16	 hours	 of	






Financial	 support	 provided	 by	 the	 Netherlands	 Organization	
for	Scientific	Research	(PhD	grant	to	TMW)	and	The	European	
Research	 Council	 (ERC	 consolidator	 grant	 to	 NIM,	 grant	
agreement	no.	725523).	
Abbreviations	
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The three glycine residues present in the laspartomycin macrocycle demonstrate 
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